Cancer research is by far one of the most demanding, fascinating and profitable industries in the world. This line of work has a specific purpose, and that purpose is to save as many lives as possible. Unfortunately, many cancer research companies don’t have the best of capabilities to put a huge enough dent in cancer’s ill effects. Though they tend to do their best by trying, these companies usually go bankrupt during the process. The thing about cancer research is that a company must produce products that are strong enough to rid the body of the disease while being gentle enough on the human body. You can’t have one without the other, and if you do, results will be few and far between.
Seattle Genetics is the dominating force in cancer research as this biotech company has great leadership. This leadership comes in the form of Dr. Clay Siegall. Siegall has been around for decades, and he has become a well-respected individual within this exclusive community. He has a B.S. in Zoology as well as a Ph.D in Genetics. The guy has literally won numerous amounts of philanthropic awards thanks to what he’s doing in cancer research. The company wasn’t always the worldwide leader as it struggled in its first few years of existence. Daily operations are expensive and Seattle Genetics’ funds were depleting in a rapid rate. This only caused Siegall and the company to hunker down. He hired a dynamic sales team to pull the company from the depths and with the company’s unique medications, Seattle Genetics took off to new levels of success.
Siegall stated that Seattle Genetics didn’t really start making big profits until around 10 years ago. After its Initial Profit Offering (IPO), the company found its footing and never looked back. As of today, Seattle Genetics’ stock has basically tripled in over a five-year time frame. It now produces some of the most advanced cancer fighting medications in history and everything is controlled by Dr. Clay Siegall.